Lunula combines two therapeutically beneficial wavelengths: 405 and 635 nm. Each wavelength is capable of stimulating a specific cascade to effectively and safely treat onychomycosis. As a result, the Lunula provides a treatment absent of any adverse events while inducing key pathways to effectively...See more
Headquarters:
Australia
Company Type:
SME
Company size:
Employees
Address:
null
LOW
spending power
